UNIVERSITY OF CALIFORNIA, IRVINE

Neuvivo has submitted an NDA to the FDA for NP001, an ALS treatment that could be the first disease-modifying therapy restoring balance to the innate immune system. Phase 2 study data showed CRP levels correlated with lung function, with high CRP patients on NP001 experiencing slower VC decline. The therapy increased plasma TGFB1 levels by 95%, suggesting it resets the innate immune system. Neuvivo believes NP001 offers promise for the ALS community.

Neuvivo submitted an NDA to the FDA for NP001, an ALS treatment targeting inflammation, potentially extending survival by up to a year. NP001 aims to be the first disease-modifying therapy for ALS, addressing a critical unmet need.

SciX 2024 Conference in Raleigh, NC, features 'AES Early Career' session on Oct 21, chaired by Gongchen Sun and Robert Williamson, with talks on nonlinear electrophoresis, microfluidic CRISPR assays, nanopore ionic circuits, acoustofluidics for precision medicine, and multimodal tech for EV detection.

UC Irvine receives $3M from NSF for a Biomedical Engineering Social Science Training initiative to address cardiovascular health disparities, training graduate students in technology, equity, and community engagement.

NIH establishes pandemic preparedness research network, ReVAMPP, to develop vaccines and monoclonal antibodies for high-priority pathogens, focusing on virus families known to infect humans. NIAID commits $100 million annually to fund the program, aiming to fill knowledge gaps and enhance pandemic response capabilities.

UC Irvine received $668 million in research funding for fiscal 2023-24, a 2% increase from the previous year. The U.S. Department of Health and Human Services provided the most funding at nearly $248 million, followed by the National Science Foundation with $57 million. Notable new awards include $4 million from the NIH for a Southern California consortium, $4.3 million for malaria research in Africa, and $2.8 million from NASA for an Antarctica ice sheet survey.